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Introduction: Low testosterone level has strongly been correlated with body fat accumulation and 
abdominal obesity in men.
Objectives: This study aimed to evaluate testosterone level in men with and without metabolic 
syndrome to determine the relationship between testosterone and metabolic syndrome.  
Patients and Methods: This case-control study was conducted on 172 cases of metabolic syndrome 
and 172 participants as a control group in Rasoul Akram hospital, Tehran, Iran. Demographic 
characteristics, fasting blood sugar (FBS), high-density lipoprotein (HDL), low-density lipoprotein 
(LDL), cholesterol, triglyceride (TG), and testosterone levels were recorded. SPSS version 21.0  and 
SAS version 9.1 were used for statistical analysis. Level of significance was considered 0.05.
Results: The mean age of the two groups were 45.1 ± 9.3 years and 41.5 ± 11.2 years, respectively. There 
was a significant difference in serum testosterone levels between both groups and low testosterone 
levels were associated with metabolic syndrome (P < 0.001). Serum testosterone levels showed a 
significant negative correlation with age in the metabolic syndrome group (r = -0.16, P = 0.02). The 
relationship between metabolic syndrome and total plasma testosterone level using logistic regression 
model showed that, by increasing the total plasma testosterone level, the odds ratio for metabolic 
syndrome was 0.076 (95% CI: 0.027-0.216; P < 0.001). 
Conclusion: According to the results, low level of testosterone was related to the presence of metabolic 
syndrome in adult males. Future studies can investigate diagnostic value of testosterone level in this 
syndrome.
ABSTRACT
Implication for health policy/practice/research/medical education:
In a case-control study on 172 cases of metabolic syndrome, we found a significant difference in serum testosterone levels between both 
groups. Serum testosterone levels showed a significant negative correlation with age in the metabolic syndrome group too. 
Please cite this paper as: Hejrati A, Ziaee A, Pourmahmoudian M, Bayani E, Ghavamipour M, Saatchi M. Association of plasma total 
testosterone level and metabolic syndrome in adult males. J Nephropathol. 2020;9(3):e27. DOI: 10.34172/jnp.2020.27.
Introduction
Metabolic syndrome is one of the main threats to public 
health in the 21st century according to its association 
with type 2 diabetes mellitus and cardiovascular diseases 
(1). It is characterized with insulin resistance, abdominal 
obesity, hypertension, renal disease, hyperglycemia, and 
dyslipidemia profile (2). These factors lead to the high 
prevalence of cardiovascular diseases and diabetes (3). The 
prevalence of metabolic syndrome is growing worldwide 
especially in children and young adults (4,5).
Since metabolic syndrome has several components 
such as metabolic, cardiovascular and anthropometric 
factors, it is complicated to understand the etiology of 
this syndrome. The risk factors of metabolic syndrome 
affecting testosterone level can be demonstrated easily 
because of their correlation with waist circumference; such 
as overweight-obesity, lifestyle, surgery, aging, diabetes 
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Low testosterone level has strongly correlated with 
body fat accumulation and abdominal obesity in men (8). 
Testosterone is a sex hormone in males which is produced 
by testicular Leydig cells (9). It increases lipolysis and 
decreases visceral fat, while lack of testosterone leads 
to insulin resistance due to increased fatty acids (10). 
Endogenous androgens decreased with increasing age 
in men and it is associated with cardiovascular diseases, 
diabetes and hypertension. However, there is not 
sufficient evidence to show the relationship between low 
testosterone levels and male obesity (11,12). 
Objectives
This case-control study was performed to investigate 
the relationship of testosterone levels with metabolic 
syndrome in Iranian men. It is promising to provide 
ground work for further studies to use testosterone levels 
and testosterone analogs to predict or treat this syndrome.
Patients and Methods
Study design
This case-control study was conducted on patients of 
internal medicine clinic in Rasoul Akram hospital, Tehran, 
Iran. Participants were categorized into two groups. First 
group consisted of 172 patients with metabolic syndrome 
and the second group consisted of 172 patients who 
referred to the clinic for other complaints irrelevant to 
metabolic syndrome and did not have metabolic syndrome. 
Using ATP III (adenosine triphosphate) criteria patients 
with metabolic syndrome were diagnosed. The ATP III 
declared presentation of metabolic syndrome if three or 
more of these five criteria are met;
1.	 Waist circumference over 102 centimeters in men or 
88 centimeters in women,
2.	 Systolic blood pressure over 130 mm Hg and diastolic 
blood pressure over 85 mm Hg,
3.	 Fasting triglyceride (TG) level over 150 mg/dL,
4.	 Fasting high-density lipoprotein (HDL-C) level less 
than 40 mg/dL in men or 50 mg/dL in women,
5.	 Fasting blood sugar (FBS) levels over 100 mg/dL or 
diagnosed type 2 diabetes.
Patients with micro and macro-vascular complications 
from diabetes or any other complication were not 
included in this study. The control group and the 
metabolic syndrome group were chosen to be similar in 
demographic features as much as possible.
The collected data were entered into a pre-designed 
checklist consisting of; demographic features (age, weight, 
height, Body mass index [BMI]), FBS, HDL, LDL, total 
testosterone, cholesterol, and TG. Blood samples (10 ml) 
were collected in mornings from participants with at least 
10-hour fasting. All samples were tagged and labeled to 
minimize misunderstandings. Serum levels of cholesterol, 







No. % No. %
20-39 30 17.4 63 36.2
40-59 135 78.5 101 0.58
Over 60 7 4.1 7 4.1
TG, and FBS were measured by photometry, HDL and 
LDL levels were assessed using enzymatic direct tests, 
and total testosterone with chemiluminescence (ECL) 
method.
Ethical issues
The research followed the tenets of the Declaration of 
Helsinki. Informed consent was obtained from all patients. 
The study was approved by the ethical committee of Iran 
University of Medical Sciences (ethical code; IR.IUMS.
FMD.REC.1396.8911215299). This work supported 
by deputy research and technology of Iran University of 
Medical Sciences in Iran (Research code: 2938).
Statistical analysis
Statistical analysis was done using Statistical Package for 
Social Sciences, version 21.0 (IBM SPSS Statistics Inc., 
Chicago, IL, USA) and Statistical Analysis Software, 
version 9.1 (SAS Institute Inc., Cary, NC, USA). Mean 
± standard deviation (SD) was reported to describe 
quantitative variables; and categorical data were described 
using counts and percentages. T test was used to 
compare quantitative variables with normal distribution 
and quantitative variables without normal distribution 
were analyzed by Mann-Whitney test. To compare 
the qualitative variables, Chi square test and Fisher’s 
exact test was used. Correlations between quantitative 
variables were tested using Spearman’s rank correlation 
and Pearson’s correlation coefficient. Additionally, to 
investigate confounding factors, multivariate logistic 
regression analysis was implemented and results were 
expressed by odds ratio (95 percent confidence interval). 
Level of significance was considered 0.05.
Results
The mean age for the metabolic syndrome group was 45.1 
± 9.3 years and for the control group 41.5±11.2 years. The 
participants were categorized into three age groups (20-39, 
40-59, and over 60 years) demonstrated in Table 1. The 
means and ranges for quantitative variables are described 
in Table 2. In participants with metabolic syndrome 
a significant negative correlation between age and 
testosterone level was observed (r=-0.16, P = 0.02; Figure 
1), but this correlation was not recorded in the control 
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group (P = 0.211). Serum testosterone levels did not show 
any significant correlation with waist circumference, 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), FBS, cholesterol, LDL-C, HDL-C, TG, and 
BMI in any either of the groups. As demonstrated in 
Table 2, mean testosterone serum levels for metabolic 
syndrome group and control group are 4.7 ± 1 ng/mL 
and 7.2 ± 1.3 ng/ml respectively, which was significantly 
different (P < 0.001). The relationship between metabolic 
syndrome and total plasma testosterone level using logistic 
regression model showed that, by increasing the total 
plasma testosterone level, the odds ratio for metabolic 
syndrome was 0.076 (95% CI: 0.027-0.216) (P < 0.001). 
The results also showed that by increasing one unit of 
FBS, the odds ratio for metabolic syndrome was 1.425 
(95% CI: 1.267-1.604) (P < 0.001). Other variables such 
as age, waist, SBP, DBP, serum cholesterol, FBS, LDL-C, 
HDL-C, BMI and TG had no significant correlation 
with metabolic syndrome (P > 0.05). Table 3 shows the 
results of the logistic regression model for the association 
between metabolic syndrome with variables of age, waist, 
SBP, DBP, symptom-limited treadmill test (SLTT), serum 
cholesterol, LDL-C, HDL-C, TG and also BMI.
Discussion 
Metabolic syndrome is recognized as an important risk 
that predisposes patients to cardiovascular disease and 
type II diabetes and also renal disease (13). According to 
WHO’s statistical data, cardiovascular disease is the major 
reason of mortality and morbidity in the world (14). The 
prevalence of death caused by cardiovascular in men is 
higher than women (15). Recent studies suggest that low 
testosterone levels have correlation with cardiovascular 
damage, as testosterone has a key role in decreasing serum 
levels of pro-inflammatory factors such as interleukin 1 
and tumor necrosis factors. Furthermore, testosterone 
Table 2. Participants age groups
Variable
Patients with metabolic syndrome Patients without metabolic syndrome
Mean SD Range Mean SD Range
Age (y) 45.1 9.3 20-84 41.5 11.2 20-84
Waist circumference (cm) 96.6 11.3 72-189 90.4 9.1 72-130
Systolic BP (mm Hg) 12.8 17.1 80-165 115.1 16 85-200
Diastolic BP (mm Hg) 77.6 12 50-115 72 10.7 50-100
FBS (mg/dL) 119.5 43.6 83.5-444 90 5.6 73.5-108
Cholesterol (mg/dL) 194.1 38.3 104-296 175.6 32.5 106-257
LDL-C (mg/dL) 114.6 24.7 59-182 103.3 24.1 54-169.1
HDL-C (mg/dL) 37 8 15.3-60.5 39.7 7.3 25-71
TG (mg/dL) 194.9 101.2 41-688 145.7 76.8 52-496
BMI (kg/m2) 26.3 3.4 16.4-34.9 24.8 3.2 17.5-32.5
Testosterone serum level (ng/mL) 4.7 1 2.5-7.6 7.2 1.3 4.2-9.5
FBS, Fasting blood sugar; BMI, body mass index; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BP, 
blood pressure.
Figure 1. Correlation between serum testosterone level and age in 
metabolic syndrome group.
Table 3. Logistic regression model for metabolic syndrome with age, waist, SBP, 





Age 0.95 0.884 1.033 0.255
Waist 1.056 0.924 1.207 0.425
SBP 0.959 0.897 1.024 0.211
DBP 1.021 0.940 1.110 0.616
FBS 1.425 1.267 1.604 <0.001
CHOL 1.021 0.971 1.073 0.414
LDL-C 0.989 0.929 1.053 0.730
HDL-C 1.078 0.974 1.194 0.148
BMI 0.937 0.660 1.328 0.713
SLTT 0.076 0.027 0.216 <0.001
TG 1.008 0.997 1.019 0.143
FBS, Fasting blood sugar; BMI, body mass index; TG, triglyceride; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
SLTT, symptom-limited treadmill test; SBP, systolic blood 
pressure; DBP, diastolic blood pressure.
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increases anti-inflammatory cytokine interleukin 10. It has 
been proved that testosterone improves insulin sensitivity 
and reduces BMI and visceral fat (16). In the past decades, 
several studies have shown that low- testosterone serum 
levels in men correlate strongly with obesity (17). In this 
study we reported a significant association between low 
levels of testosterone and metabolic syndrome in adult 
males. Additionally, we recorded that, testosterone levels 
and age in patients with metabolic syndrome have negative 
correlation. A similar investigation was conducted by 
Kaplan et al, which showed that old men with metabolic 
syndrome show a significant reduction in testosterone 
serum levels (18) which was consistent with our results.
Moreover, a cross-sectional study in 2016 demonstrated 
that the prevalence of metabolic syndrome and its 
components increase with age especially with high BMI 
and lack of physical activity and obesity. This study 
had a large population about 20 000 participants, since 
it consisted of men and women which makes its result 
more reliable (19). A study conducted by Mahdy et al in 
Egyptian population investigated the levels of testosterone 
and sex hormones in men with metabolic syndrome. Their 
study showed that low testosterone levels have conversely 
correlation with weight, BMI, cholesterol, LDL-C, TG 
and insulin as our findings. They also find a positive 
correlation between low-testosterone levels and HDL-C. 
In our study, we could not find a significant association 
between HDL-C and serum testosterone levels. Mahdy 
et al studied only 40 men with metabolic syndrome and 
40 men as a control group, so their results need further 
investigation according to sample size (20).
A meta-analysis in 2011 by Brand et al revealed the 
correlation of sex-dependent testosterone levels and 
metabolic syndrome. This study also investigated this 
relationship in women. Testosterone levels in women 
with metabolic syndrome were higher, though they 
were lower in men with metabolic syndrome. Brand et 
al observed variability in results because of differences in 
age, BMI, metabolic syndrome criteria and study design. 
They also demonstrated the higher sex hormone binding 
globulin (SHBG) levels are associated with decreased 
metabolic syndrome risk in both genders (21). Siddiqui 
et al supported an association between SHGB levels and 
metabolic syndrome. In their cross-sectional study, among 
Saudi men population, SHBG levels have correlation 
with age, BMI, TG, HDL-C, and testosterone levels (22). 
Accordingly, Cunningham stated that low-testosterone 
and SHBG serum levels are due to increased insulin and 
inflammatory cytokines. Since low-testosterone levels 
are associated with cardiovascular disease in men; the 
relationship is not clear and seems to be independent 
from metabolic syndrome (3). We, therefore, suggested 
conducting future studies to investigate serum SHBG 
levels in metabolic syndrome without the effect of 
testosterone levels. 
Haring et al in prospective cohort study suggested low-
testosterone levels as a prognostic factor for incident of 
metabolic syndrome especially in young and middle-aged 
men. However, they cannot demonstrate the relationship 
between low-testosterone levels and metabolic syndrome. 
Similar to before studies, they cannot affirm whether 
low-testosterone causes it or is an early mechanism 
leading to metabolic syndrome (23). Recent studies 
show testosterone replacement therapy reduces insulin 
resistance in men with diabetes and metabolic syndrome. 
Testosterone replacement therapy also has significant 
effect on reduction of body fat mass, weight loss and 
decreases waist circumference in men with metabolic 
syndrome (24). However, it is suggested conducting 
further investigations to understand the relationship 
between serum testosterone levels and metabolic syndrome 
in a larger group and longitudinal studies. Moreover, it 
requires more exploration to recognize specific tissue 
actions of testosterone because testosterone replacement 
therapy has considerable effects on insulin and fat mass.
Conclusion
According to the results, low-level of testosterone was 
related to the presence of metabolic syndrome in adult 
males. Future studies can investigate diagnostic value of 
testosterone level or therapeutic effects of testosterone 
analogs to treat this syndrome.
Limitations of the study
It had some limitations including lack of follow-up of 
patients, which would demonstrate long-term metabolic 
outcomes. However, it was beyond the objective of the 
present study due to the case-control nature of the study. 
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